Z Gastroenterol 2017; 55(08): e57-e299
DOI: 10.1055/s-0037-1604957
Kurzvorträge
Pankreas
Tumormicroenvironment: Relevanz für das Pankreaskarzinom: Freitag, 15 September 2017, 14:40 – 16:00, Coventry/Forschungsforum 4
Georg Thieme Verlag KG Stuttgart · New York

Is hyaluronan deposition in the stroma of pancreatic ductal adenocarcinoma of prognostic significance?

M Kemper
1   University Medical Centre Hamburg-Eppendorf, Hamburg, Department of General, Visceral and Thoracic Surgery, Hamburg, Deutschland
,
P Prehm
2   University Medical Centre Hamburg-Eppendorf, Hamburg, Centre for Diagnostic, Department of Pathology, Hamburg, Deutschland
,
G Sauter
2   University Medical Centre Hamburg-Eppendorf, Hamburg, Centre for Diagnostic, Department of Pathology, Hamburg, Deutschland
,
U Schumacher
3   University Medical Centre Hamburg-Eppendorf, Hamburg, Germany, Centre of Experimental Medicine, Department of Anatomy and Experimental Morphology, Hamburg, Deutschland
,
JR Izbicki
1   University Medical Centre Hamburg-Eppendorf, Hamburg, Department of General, Visceral and Thoracic Surgery, Hamburg, Deutschland
,
F Gebauer
1   University Medical Centre Hamburg-Eppendorf, Hamburg, Department of General, Visceral and Thoracic Surgery, Hamburg, Deutschland
› Author Affiliations
Further Information

Publication History

Publication Date:
02 August 2017 (online)

Also available at
 

Introduction:

Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis and the number of PDAC-related deaths is rising. Recently the tumour stroma and in particular one of its main components, hyaluronan (HA), have attracted considerable attention as intravenous hyaluronidase treatment together with conventional chemotherapy considerably prolonged survival in HA-rich PDA patients.

Objective:

The aim of the study was to investigate the prognostic significance of HA deposition in PDA using both antibodies to HA and hyaluronan binding protein (HABP).

Material and methods:

Tissue microarrays of PDAs of 184 patients and pancreatic xenografts tumours were immunohistochemically (IHC) stained for HA using either biotinylated hyaluronic acid binding protein (HABP) or anti-HA antibody.

Results:

HABP but not anti-HA antibody staining showed specific HA detection in PDAC confirmed by hyaluronidase predigestion of tissue sections. HA was expressed in 162 patients (86.4%) with extracellular distribution within the tumour and no intracellular accumulation of HA within tumour cells, HA positivity as determined by HABP was associated with larger primary tumours (p = 0.046). Kaplan-Meier survival analysis failed to show significant differences in disease-free and overall-survival.

Conclusion:

Patients with high HA expression did not show a different OS compared to those with missing HA expression in the tumor stroma and should be therefore not considered as prognostic marker in PDAC. However, as HA has been known as promoter for cell proliferation, migration and neo-agniogenesis. As almost 90% of the tumours were HA positive, the expression of HA is likely to be of great importance during tumour progression in PDAC, as illustrated by the extensive desmoplastic reaction in almost every PDAC. Obviously HA expression becomes mandatory at some point during tumour progression in order to provide an optimized tumour microenvironment for further tumour growth.